White or industrial biotechnology implements microorganisms/enzymes for the large-scale production of plastics, chemicals, agricultural, food, and pharmaceutical products/energy carriers Renewable raw materials like forestry and agricultural waste are used for metabolic engineering and downstream processing. It utilizes enzymes and microorganisms for preparing products like paper, pulp, detergents, fuels, etc., to minimize pollution, and for resource conversion.
The application of advanced biotech processes in several industrial activities is transforming the manufacturing processes for an array of biological products and byproducts. The market revolution is also driven by related technological developments in genomics, bioinformatics, and proteomics. There are extensive R&D activities that are being conducted by the industry players in attempts to enhance the yields and efficiencies from large scale bioprocessing.
Working in Harmony with the Environment
With the application of industrial biotechnology there is significant possibility to implement large-scale biological manufacturing while preventing pollution, conserving resources, and reducing operating cost. The complete commercial development of this third wave in biotechnology can have potential advantageous impact, on the global health care and agricultural biotechnology scenario.
For instance, the earliest example of how industrial biotechnology has been implemented with pollution prevention in mind was how the biotechnology companies developed stain removing enzymes, thereby directly reducing the overall usage of phosphates and preventing the associated problems of algal blooms in surface waters around the globe along with simultaneously enhancing the outcomes with the usage of non-polluting bio-based additives.
Downstream processing and metabolic engineering
As opposed to the conventional processes, white biotechnology processes can be run in milder reaction conditions with modest temperatures. The usage of aqueous media further diminishes the energy necessities and the number of unwanted by-products. However, as the product concentrations and rate of formation are regularly very low, products have to be purified to produce reasonable marketable quantities.
This purification process is referred to as downstream processing. Market entities are invested in developing ways to optimize the manufacturing processes or biocatalysts used, for example by enhancing key metabolic processes and switching reducing less important process using metabolic engineering. Optimizing enzymes by directed evolution through enzymatic engineering can also aid in bioproduction enhancement.
Notable trends in Industrial Biotechnology
• Development of CRISPR Technology enzyme development
CRISPR technology is guided by RNA to modify a genome at a target sequence, thereby enhancing the effectiveness of gene editing therapies. The market for CRISPR is majorly driven by the growing number of possible implementation scenarios where gene editing can provide viable options to enhance biological yield.
Organs-on-chips use microfluid channels to mimic the three-dimensional microenvironment of living organs and are potential alternatives to traditional animal testing methods. CN Bio Innovations, Emulate Inc., and Cherry Biotech are among the few players manufacturing automated organs-on-chips that is used for drug testing in vitro and for accurately predicting drug toxicity.
The market is witnessing numerous collaborations to broaden their product portfolios, validate the existing product efficiency, and strengthen their foothold in the global market. For instance, in 2017 CN Bio entered in a partnership with the FDA to test the efficiency of its organ-on-a-chip technology for predicting a drug response during clinical trials.
• Miniaturized bioreactors
Miniaturized stirred bioreactors (MSBRs) are gaining market traction as they facilitate cost-effective and rapid bio-process development. The utility of high-throughput miniaturized bioreactors for cell culture process development has enhanced scalability, reproducibility, and control of cell growth and viability.
The industrial biotechnology sector has gained a significant amount of attention during the past several years and is estimated to grow exponentially over the forecast time frame. Industry players have joined hand with their fellow contenders to strengthen and commercialize the generic biotechnology industry.
In an attempt to facilitate the development of personalized medicine, the players are focusing on increasing their investments in the research and development of bio-recombinant proteins and biopharmacy. For instance, the German government formulated the “National Research Strategy BioEconomy 2030” to make extensive use of renewable resources as a raw material for industrial biotechnological processes.
Furthermore, in 2011 the government also launched “Industrial Biotechnology Innovation Initiative” with an aim to encourage R&D into biotechnological methods for goods manufacturing from renewable resources and substituting the use of fossil raw materials. Also, the FDA plans to test drug toxicity, metabolism, and drug-drug interactions to effectively assess a drug’s success in clinical trials.
Some of the key players operating in the market comprise of Amyris, Borregaard, BioAmber, Codexis, Evolva, Novozymes, Deinove, Fermentalg, Global Bioenergies, Gevo, Metabolic Explorer, and Solazyme.
Name – Rubik Angelo Barar (Assistant Manager – Advanced Diagnostics & Biotechnology/Pharmaceuticals – Healthcare GVR)
Educational Qualification – Bachelor in Bioinformatics & MBA in Financial Management, PGDM Data Analytics, CFP®, pursuing CFA®
Professional Experience – Rubik has ~7 years of research experience working on extensive market tracking and in-depth statistical revenue flow analysis of markets in the Advanced Diagnostics, Genomics & Bioinformatics segments. He is one of the core members of the team of analysts at Grand View Research and is known for his ability to suggest innovative solutions without losing sense of the fundamentals.
Consulting/Domain Expertise – Rubik manages three teams of analysts who specifically track the advanced diagnostics, genomics & bioinformatics and pharmaceutical segments of the Healthcare domain. He has successfully executed over 95+ client-sponsored research projects, directly working with key fortune 500 companies, catering to their specific research needs. His ability to understand research problems and to prepare thorough analysis of key market variables are skills well appreciated by the clients as well as his superiors.